EHA 2023 | Pelabresib in myelofibrosis: the MANIFEST trials

Haifa Kathrin Al-Ali • 11 Jun 2023

EHA 2023

Haifa Kathrin Al-Ali, MD, Martin Luther University of Halle-Wittenberg, Halle, Germany, discusses the ongoing Phase III MANIFEST-2 trial (NCT04603495), investigating a combination treatment of pelabresib and ruxolitinib in patients with myelofibrosis (MF) who have not previously been treated with a JAK inhibitor (JAKi). This trial follows from a Phase II trial (NCT02158858), which showed a significant spleen response in patients treated with pelabresib monotherapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research support from Novartis, Bristol Myers Squibb and Incyte,
participating on a scientific advisory board for Novartis, Bristol Myers Squibb, Abbvie, SGK, Blue Print, AOP Pharma
travel grant from Bristol Myers Squibb and Abbvie